Protara Beats Q2 Loss Estimates
Protara Therapeutics (NASDAQ:TARA), a clinical-stage biotechnology company focused on treatments for cancer and rare diseases, reported its second quarter 2025 financial results on August 11, 2025. The headline result was a GAAP net loss per share of $0.35, which was narrower than the analyst consensus estimate of a $0.39 GAAP loss. Revenue (GAAP) matched projections at $0.0 million, Revenue remained at zero year-over-year, as the company is not yet commercial. Operational losses (GAAP) increased, driven by higher research and development and general administrative expenses. Overall, the quarter reflected substantial investment in clinical programs, a solid liquidity position, and ongoing progress, but also continued losses and no revenue from product sales.
Source: Analyst estimates for the quarter provided by FactSet.
Protara is focused on developing new therapies for cancer and rare disorders with few available treatments. Its lead asset is TARA-002, a biologic candidate being investigated in bladder cancer and pediatric lymphatic malformations. The company is also developing intravenous Choline Chloride for patients who require long-term nutrition support through parenteral (intravenous) means due to digestive system failure.
Source Fool.com
